CRBN and plasma cell myeloma: The immunomodulatory drugs (IMiDs; e.g., thalidomide, lenalidomide, and pomalidomide) targeting E3 ubiquitin ligase complex component cereblon (CRBN) are another group of drugs approved by FDA, that by binding with CRBN, switch the substrate specificity, and ultimately lead to the degradation of critical pro-survival proteins in multiple myeloma [11].